0.119
0.00 (0.00%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (SG) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Pharmesis Intl | - | - |
Stockmoo Score
Similar Stocks
| Stock | Market Cap | DY | P/E | P/B |
|---|---|---|---|---|
| PHARMESIS INTL | 4 M | - | - | 0.430 |
| TJ DARENTANG USD | 3 B | 8.60% | 12.53 | 1.84 |
| IX BIOPHARMA | 25 M | - | - | 2.64 |
|
Pharmesis International Ltd is an investment holding company. The company manufactures pharmaceutical products in the form of tablets, granules, pills, and other forms. Its operating segments are Western drugs, which are chemically formulated drugs and are marketed under the Kinna brand; TCM-formulated drugs, which refer to Traditional Chinese Medicine and are marketed under the Longlife brand; and Distribution. The company derives revenue from the sale of medicines to domestic customers in China. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Chung (Chia-Jung) | 31 Jul 2023 | 5,233,800 (16.51%) |
| Suntar Investment Pte. Ltd. | 05 Apr 2023 | 4,770,000 (15.05%) |
| Yu (Yi Wen) | 05 Apr 2023 | 3,450,000 (10.88%) |
| Shenzhen Sichuang Meishi Pharmaceuticals R&D Co., Ltd. | 05 Apr 2023 | 3,000,000 (9.46%) |
| Top Entrepreneur Limited | 05 Apr 2023 | 2,281,200 (7.20%) |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |